Open & Flex­i­ble Tech­nol­o­gy Can En­able Break­through In­no­va­tion

The bound­aries of in­no­va­tion in the life sci­ences in­dus­try are be­ing pushed like nev­er be­fore, as the world races to­ward the de­vel­op­ment of an ef­fec­tive COVID-19 vac­cine. At the same time, with at least 6,500 clin­i­cal tri­als at risk of be­ing dis­rupt­ed by the pan­dem­ic, life sci­ences com­pa­nies are strug­gling to keep their cur­rent re­search and clin­i­cal de­vel­op­ment pro­grams on track.

Against this back­drop, many com­pa­nies are op­er­at­ing with­in a frag­ment­ed tech­nol­o­gy land­scape, us­ing mul­ti­ple plat­forms and so­lu­tions that trap da­ta in pro­pri­etary tech­nol­o­gy si­los – slow­ing the abil­i­ty to in­no­vate at speed and scale. IDC, a glob­al provider of mar­ket in­tel­li­gence and ad­vi­so­ry ser­vices, sur­veyed 120 phar­ma­ceu­ti­cal and biotech­nol­o­gy lead­ers and found that 94% said the abil­i­ty to eas­i­ly ac­cess, use and ap­ply an­a­lyt­ics and ar­ti­fi­cial in­tel­li­gence (AI) to da­ta from across func­tion­al ar­eas was im­por­tant to achiev­ing their busi­ness strat­e­gy. Yet, more than 50% said they did not have a clear path to­ward achiev­ing that goal. And in an­oth­er re­cent sur­vey, 88% of life sci­ences ex­ec­u­tives said that dig­i­tal­iza­tion at their com­pa­nies is still hap­pen­ing in si­los.

Shift­ing to an open, cloud-based ap­proach could pro­vide the flex­i­bil­i­ty, ex­ten­si­bil­i­ty and con­nec­tiv­i­ty to make a step-lev­el change pos­si­ble in how com­pa­nies dig­i­tal­ly in­te­grate across the en­ter­prise. Im­proved ac­cess to a wide range of da­ta would en­able the ap­pli­ca­tion of AI and ad­vanced an­a­lyt­ics, de­liv­er­ing in­sights that could bring new drugs and ther­a­pies to pa­tients faster than ever be­fore.

In­sights en­abled by AI are al­ready play­ing a role in speed­ing up drug de­sign and de­vel­op­ment. In Jan­u­ary, Ex­sci­en­tia and Sum­it­o­mo Dainip­pon Phar­ma an­nounced that a drug mol­e­cule to treat ob­ses­sive-com­pul­sive dis­or­der – de­signed with AI al­go­rithms – was ready for clin­i­cal tri­als af­ter just 12 months in de­vel­op­ment, when a typ­i­cal dis­cov­ery and de­vel­op­ment phase can take 3 to 4 years.

All of the news, delivered with full-text to your inbox. For professionals discovering, developing, and marketing biopharmaceutical drugs.

SIGN UP

A Plat­form to En­able End-to-End Con­nec­tiv­i­ty

One new tech­nol­o­gy plat­form lever­ages a com­bi­na­tion of Google Cloud’s ad­vanced an­a­lyt­ics and AI ca­pa­bil­i­ties, to­geth­er with Ac­cen­ture’s life sci­ences ser­vices and tech­nol­o­gy ex­per­tise. Of­fer­ing prod­uct suites in re­search, clin­i­cal, phar­ma­covig­i­lance, reg­u­la­to­ry and pa­tient ser­vices, the IN­TIENT plat­form is de­signed to help life sci­ences or­ga­ni­za­tions make their da­ta more ac­ces­si­ble, se­cure and valu­able.

IN­TIENT al­so en­ables a new lev­el of col­lab­o­ra­tion, uni­fy­ing cross-func­tion­al teams with com­mon da­ta in­sight tools and met­rics. Ca­pa­bil­i­ties with­in the IN­TIENT plat­form’s newest re­lease, many of which are unique to the life sci­ences in­dus­try, were de­vel­oped in less than six months from the launch of Ac­cen­ture’s part­ner­ship with Google Cloud.

Ca­pa­bil­i­ties with­in this lat­est re­lease of the Ac­cen­ture IN­TIENT Plat­form in­clude fea­tures to en­sure the plat­form is:

• Se­cure & Com­pli­ant: The plat­form of­fers ro­bust se­cu­ri­ty with end-to-end en­cryp­tion of da­ta in flight and at rest, in­clud­ing in­te­gra­tion with iden­ti­ty ac­cess man­age­ment. This de­liv­ers mul­ti-lay­ered se­cu­ri­ty to ful­fil spe­cif­ic com­pli­ance needs for the avail­abil­i­ty, pro­cess­ing in­tegri­ty, con­fi­den­tial­i­ty, and pri­va­cy of cus­tomer da­ta, in­clud­ing be­ing com­pli­ant for HIPAA, SOC, and HITRUST, and val­i­da­tion ready for GxP com­pli­ance.
• AI-Ready: The IN­TIENT Plat­form gives clients ac­cess to pow­er­ful AI ca­pa­bil­i­ties in an eas­i­ly con­sum­able pack­age – pro­vid­ing ac­cess to world-lead­ing tools like BERT and Au­toML to sup­port busi­ness and sci­en­tif­ic use cas­es rang­ing from nat­ur­al lan­guage pro­cess­ing (NLP) to in­tel­li­gent can­cer de­tec­tion in med­ical im­ages.
• Open & Scal­able: The plat­form’s com­mon run­time ca­pa­bil­i­ties en­able Google Cloud’s mul­ti-cloud and hy­brid cloud work­load de­ploy­ments with elas­tic scal­ing ca­pa­bil­i­ties. This pro­vides se­cure and flex­i­ble ap­pli­ca­tion pro­gram­ming in­ter­face (API) ac­cess to pro­tect in­vest­ments in­to ex­ist­ing soft­ware so­lu­tions and cloud plat­forms.

This lat­est plat­form re­lease al­so in­tro­duces the IN­TIENT Net­work, a part­ner ecosys­tem that lever­ages the open ar­chi­tec­ture of the Google Cloud Plat­form. With in­dus­try-stan­dard APIs, the net­work re­moves bar­ri­ers to en­try for spe­cial­ty soft­ware, ser­vices, hard­ware, con­tent, and busi­ness part­ners – en­abling rapid, flex­i­ble de­ploy­ment of new, in­no­v­a­tive so­lu­tions. With IN­TIENT, life sci­ences com­pa­nies can con­nect to small, in­de­pen­dent ven­dors of­fer­ing high­ly spe­cif­ic and unique so­lu­tions, along with an en­tire com­mu­ni­ty of proven part­ners and providers.

In this age of New Sci­ence, so­lu­tions like IN­TIENT can of­fer an end-to-end view of da­ta and en­able state-of-the art an­a­lyt­ics, help­ing the in­dus­try ad­vance new, per­son­al­ized ther­a­peu­tics faster than ever be­fore. To learn more about IN­TIENT, vis­it www.ac­cen­ture.com/IN­TIENT.